WallStreetZenWallStreetZen

NASDAQ: PRQR
Proqr Therapeutics Nv Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PRQR

Based on 1 analyst offering 12 month price targets for Proqr Therapeutics Nv

Min Forecast
$4.00+132.56%
Avg Forecast
$4.00+132.56%
Max Forecast
$4.00+132.56%

Should I buy or sell PRQR stock?

Based on 1 analyst offering ratings for Proqr Therapeutics Nv.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PRQR's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PRQR as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PRQR stock forecasts and price targets.

PRQR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-04

1 of 1

Forecast return on equity

Is PRQR forecast to generate an efficient return?

Company
N/A
Industry
66.4%
Market
180.01%

Forecast return on assets

Is PRQR forecast to generate an efficient return on assets?

Company
N/A
Industry
31.75%

PRQR earnings per share forecast

What is PRQR's earnings per share in the next 2 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$0.56
Avg 2 year Forecast
-$0.60

PRQR revenue forecast

What is PRQR's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$19.4M+1.05%
Avg 2 year Forecast
$14.6M-23.95%
Avg 3 year Forecast
$47.6M+147.5%
PRQR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PRQR revenue growth forecast

How is PRQR forecast to perform vs Biotechnology companies and vs the US market?

Company
28%
Industry
35.96%
Market
13.56%
PRQR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PRQR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PRQR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PRQR$1.72$4.00+132.56%Strong Buy
ZNTL$2.52$4.00+59.05%Hold
GALT$2.82$11.00+290.07%Buy
WHWK$3.81$7.00+83.73%Strong Buy
ELDN$3.00$8.00+166.67%Strong Buy
View Top Biotech Stocks

Proqr Therapeutics Nv Stock Forecast FAQ

Is Proqr Therapeutics Nv Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PRQR) stock is to Strong Buy PRQR stock.

Out of 1 analyst, 1 (100%) are recommending PRQR as a Strong Buy, 0 (0%) are recommending PRQR as a Buy, 0 (0%) are recommending PRQR as a Hold, 0 (0%) are recommending PRQR as a Sell, and 0 (0%) are recommending PRQR as a Strong Sell.

If you're new to stock investing, here's how to buy Proqr Therapeutics Nv stock.

What is PRQR's earnings growth forecast for 2026-2027?

(NASDAQ: PRQR) Proqr Therapeutics Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.19%.

Proqr Therapeutics Nv's earnings in 2026 is -$49,628,235.On average, 10 Wall Street analysts forecast PRQR's earnings for 2026 to be -$58,696,649, with the lowest PRQR earnings forecast at -$84,668,151, and the highest PRQR earnings forecast at -$41,196,176.

In 2027, PRQR is forecast to generate -$62,953,236 in earnings, with the lowest earnings forecast at -$78,472,920 and the highest earnings forecast at -$47,907,676.

What is PRQR's revenue growth forecast for 2026-2028?

(NASDAQ: PRQR) Proqr Therapeutics Nv's forecast annual revenue growth rate of 28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.56%.

Proqr Therapeutics Nv's revenue in 2026 is $19,231,764.On average, 10 Wall Street analysts forecast PRQR's revenue for 2026 to be $2,047,481,557, with the lowest PRQR revenue forecast at $0, and the highest PRQR revenue forecast at $6,195,230,563. On average, 8 Wall Street analysts forecast PRQR's revenue for 2027 to be $1,541,010,922, with the lowest PRQR revenue forecast at $0, and the highest PRQR revenue forecast at $2,655,098,813.

In 2028, PRQR is forecast to generate $5,015,081,285 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $11,062,911,720.

What is PRQR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PRQR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.75%.

What is PRQR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PRQR price target, the average PRQR price target is $4.00, with the highest PRQR stock price forecast at $4.00 and the lowest PRQR stock price forecast at $4.00.

The Wall Street analyst predicted that Proqr Therapeutics Nv's share price could reach $4.00 by Nov 4, 2026. The average Proqr Therapeutics Nv stock price prediction forecasts a potential upside of 132.56% from the current PRQR share price of $1.72.

What is PRQR's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: PRQR) Proqr Therapeutics Nv's current Earnings Per Share (EPS) is -$0.47. On average, analysts forecast that PRQR's EPS will be -$0.56 for 2026, with the lowest EPS forecast at -$0.80, and the highest EPS forecast at -$0.39. In 2027, PRQR's EPS is forecast to hit -$0.60 (min: -$0.74, max: -$0.45).

What is PRQR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PRQR) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.